Pomalidomide Is Active in the Treatment of Anemia Associated With Myelofibrosis

PURPOSE: Thalidomide and lenalidomide can alleviate anemia in myelofibrosis. However, their value is undermined by their respective potential to cause peripheral neuropathy and myelosuppression. We therefore evaluated the safety and therapeutic activity of another immunomodulatory drug, pomalidomide...

詳細記述

保存先:
書誌詳細
出版年:J Clin Oncol
主要な著者: Tefferi, Ayalew, Verstovsek, Srdan, Barosi, Giovanni, Passamonti, Francesco, Roboz, Gail J., Gisslinger, Heinz, Paquette, Ronald L., Cervantes, Francisco, Rivera, Candido E., Deeg, H. Joachim, Thiele, Juergen, Kvasnicka, Hans M., Vardiman, James W., Zhang, Yanming, Bekele, B. Nebiyou, Mesa, Ruben A., Gale, Robert P., Kantarjian, Hagop M.
フォーマット: Artigo
言語:Inglês
出版事項: American Society of Clinical Oncology 2009
主題:
ORIGINAL REPORTS
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC4979191/
https://ncbi.nlm.nih.gov/pubmed/19652059
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2008.21.7356
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料